Mapping biological behaviors by application of longer-lived positron emitting radionuclides

Adv Drug Deliv Rev. 2013 Jul;65(8):1098-111. doi: 10.1016/j.addr.2012.10.012. Epub 2012 Nov 2.

Abstract

With the technological development of positron emission tomography (PET) and the advent of novel antibody-directed drug delivery systems, longer-lived positron-emitting radionuclides are moving to the forefront to take important roles in tracking the distribution of biotherapeutics such as antibodies, and for monitoring biological processes and responses. Longer half-life radionuclides possess advantages of convenient on-site preparation procedures for both clinical and non-clinical applications. The suitability of the long half-life radionuclides for imaging intact monoclonal antibodies (mAbs) and their respective fragments, which have inherently long biological half-lives, has attracted increased interest in recent years. In this review, we provide a survey of the recent literature as it applies to the development of nine-selected longer-lived positron emitters with half-lives of 9-140h (e.g., (124)I, (64)Cu, (86)Y and (89)Zr), and describe the biological behaviors of radionuclide-labeled mAbs with respect to distribution and targeting characteristics, potential toxicities, biological applications, and clinical translation potentials.

Keywords: (124)I; (64)Cu; (86)Y; (89)Zr; 1,4,7,10-tetraazacyclododecane-N,N′,N″,N″′-tetraacetic acid; 1,4,7-triazacyclononane-N,N′,N″-1,4,7-triacetic acid; 1-N-(4-aminobenzyl)-3,6,10,13,16,19-hexaazabicyclo[6.6.6]eicosane-1,8-diamine; 1-oxa-4,7,1-tetraazacyclododecane-5-S-(4-isothiocyanatobenzyl)-4,7,10-triacetic acid; 3,6,9,15-tetraazabicyclo[9.3.1]-pentadeca-1(15),11,13-triene-4-S-(4-isothiocyanatobenzyl)-3,6,9-triacetic acid; CHX-A″-DTPA; DOTA; DOTA-DPhe1-Tyr3-octreotide; DOTATOC; DTPA; HPMA; Immuno-PET; Monoclonal antibodies; N-(2-hydroxypropyl)-methacrylamide; N-[R-2-amino-3-(p-isothiocyanato-phenyl)propyl]-trans-(S,S)-cyclohexane-1,2-diamine-N,N,N′,N″,N″-pentaacetic acid; NOTA; Oncology; PIB; PIP; Radioimmunoimaging; SATA; SarAr; bispecific monoclonal antibody; bsMAb; diethylenetriaminepentaacetic acid; p-SCN-Bn-PCTA; p-SCN-Bn-oxo-DO3A; p-iodobenzoate; para-iodophenyl; succinimidyl acetylthioacetate.

Publication types

  • Research Support, N.I.H., Intramural
  • Review

MeSH terms

  • Animals
  • Antibodies, Monoclonal* / pharmacokinetics
  • Antibodies, Monoclonal* / therapeutic use
  • Humans
  • Positron-Emission Tomography
  • Radioisotopes* / pharmacokinetics
  • Radioisotopes* / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Radioisotopes